With the giant union between Pfizer and Wyeth en route to being consummated, analysts are now speculating about other major mergers are to follow. Several think this could be the Year of Consolidation for pharma, including Deutsche Bank's Barbara Ryan and Credit Suisse analyst Catherine Arnold. Possibilities named by such analysts for future deals include Bristol-Myers Squibb, Biogen Idec, Schering-Plough and Amgen. FiercePharma